VIVUS to Present at the ThinkEquity Partners 4th Annual Growth Conference (FinanzNachrichten)
MOUNTAIN VIEW, Calif., Sept. 11 /PRNewswire-FirstCall/ -- VIVUS, ( Nachrichten ) Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that Leland F. Wilson, President and CEO, will present at the ThinkEquity Partners 4th Annual Growth Conference.

Iomai Receives FDA Clearance for Study Comparing Novel Flu Vaccine Patch to Traditional Injectable Vaccine (PR Newswire via Yahoo! Finance)
Iomai Corporation announced today that it has received clearance from the U.S. Food and Drug Administration to launch a head-to-head trial comparing its needle-free, patch-based influenza vaccine with the traditional vaccine, delivered via intramuscular injection.

Ranbaxy Receives FDA Approval to Market Loperamide Hydrochloride and Simethicone Tablets (PR Newswire via Yahoo! Finance)
Ohm Laboratories Inc. , a wholly owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg .